Huyabio Validates HBI-3000 for Atrial Fibrillation Treatment
14 Nov 2024 //
PR NEWSWIRE
HUYABIO Presents Phase 2 Data on HBI-8000 + Nivolumab in Melanoma
08 Nov 2024 //
PR NEWSWIRE
HUYABIO Files an NDA with the FDA for the Novel SHP2 Inhibitor HBI-2376
31 Aug 2021 //
PRNEWSWIRE
HUYA Bioscience Presents Positive Data On HBI-8000 at Society for Immunotherapy
09 Nov 2020 //
PRNEWSWIRE
HUYA Bioscience International Licenses the Novel SHP2 Inhibitor HBI-2376
05 Aug 2020 //
PRESS RELEASE
HUYA International Licenses the Novel SHP2 Inhibitor HBI-2376
04 Aug 2020 //
PRNEWSWIRE